ZENITH Trial Breakthrough: Winrevair Shows Significant Impact on Outcomes of Pulmonary Arterial Hypertension Medha Baranwal4 Dec 2024 8:00 PM ISTUSA: In patients with advanced pulmonary arterial hypertension (PAH), adding the biologic sotatercept-csrk (Winrevair; Merck) to the maximum tolerated...
USFDA grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan for Metastatic Nonsquamous Non Small Cell Lung Cancer with EGFR Mutations: Merck Ruchika Sharma4 Dec 2024 1:01 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA) has granted...
Merck's Injectable Keytruda Proves Effective in Trial, Promises Easier Cancer Treatment Farhat Nasim20 Nov 2024 2:01 PM ISTMerck was testing the injectable version of the world's biggest selling drug in a late stage trial of patients with a type of lung cancer.
Merck gets positive EU CHMP opinion for Keytruda plus Chemotherapy as first-line treatment for adult patients with unresectable non-eithelioid Malignant Pleural Mesothelioma Ruchika Sharma19 Nov 2024 2:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency's Committee for Medicinal...
Ginkgo Bioworks advances collaboration with Merck to improve Biologics manufacturing Ruchika Sharma14 Nov 2024 12:33 PM ISTBoston: Ginkgo Bioworks has announced the completion of the first milestone of a previously announced partnership with Merck, known as MSD outside of...
Merck, Moderna begin Phase 3 Trial of V940 with Keytruda in non small lung cancer Ruchika Sharma3 Nov 2024 10:00 AM ISTRahway: Merck, known as MSD outside of the United States and Canada, and Moderna, Inc., announced the initiation of INTerpath-009, a pivotal...
Merck acquires cancer therapy developer Modifi Biosciences Ruchika Sharma31 Oct 2024 11:00 AM ISTNew Haven: Modifi Biosciences, Inc., has announced that the company has been acquired by Merck, known as MSD outside of the United States...
Merck's KEYTRUDA Gains European Approval for Two New Gynecologic Cancer Treatments MD Bureau25 Oct 2024 5:47 PM ISTWith these approvals, KEYTRUDA is now authorized for 30 indications in the EU, including five in gynecologic cancers, Merck said in a statement.
Merck eyes more acquisitions for life science after USD 600M Mirus Bio deal MD Bureau20 Oct 2024 10:15 AM ISTMerck also said it will intensify the in licensing of drug candidates in its Healthcare division.
Merck's RSV antibody Clesrovimab for infants shows 60.4% effectiveness in mid-to-late stage clinical trial MD Bureau19 Oct 2024 12:15 PM ISTThe drug clesrovimab also helped reduce RSV associated hospitalizations by 84.2% compared to placebo, Merck said.
Abbott's review plea challenging NPPA ceiling price fixation of 18 formulations rejected by DoP Farhat Nasim16 Oct 2024 4:59 PM ISTNew Delhi: The Department of Pharmaceuticals (DoP) has dismissed two review applications filed by Abbott Healthcare Private Limited (AHPL) challenging...
MSD Phase 3 trial of head and neck cancer treatment meets primary endpoint Ruchika Sharma13 Oct 2024 10:00 AM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the Phase 3 KEYNOTE-689 trial evaluating KEYTRUDA...
